Condition 1: Hypertension. Condition 2: Central obesity. Condition 3: High density lipoprotein deficiency. Condition 4: hypertriglyceridaemia. Condition 5: High blood Glucose. high blood pressure Localized adiposity High density lipoprotein deficiency hypertriglyceridaemia Hyperglycemia, unspecified
Conditions
Interventions
Intervention 1: Intervention group of apple cider vinegar tablets containing 400 to 500 milligrams of active ingredient of apple vinegar Manufactured with American Bronson company twice a day after
Treatment - Drugs
Intervention group of apple cider vinegar tablets containing 400 to 500 milligrams of active ingredient of apple vinegar Manufactured with American Bronson company twice a day after lunch and dinner
The control group received placebo pills (placebo) with the same dimensions of the original drug (apple vinegar tablets) will be. And will have no pharmacological effect. Twice a day, immediately afte
Sponsors
Ardabil University of Medical Sciences
Eligibility
Sex/Gender
All
Age
20 Years to 60 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: patients with metabolic syndrome twenty to sixty years old Exclusion criteria: Pregnant patients; nursing mothers; smokers; consumers of alcohol; drugs; patients with type I diabetes; significant impairment of renal function; thyroid disorders; liver disorders; acute and chronic inflammatory diseases; lack of mobility; recent surgery; myocardial infarction; any cerebrovascular accident in the last quarter
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Metabolic syndrome. Timepoint: Before the intervention and after three months of intervention. Method of measurement: According to criteria of ATPIII three or more of the following criteria for diagnosis of metabolic syndrome is in the Middle East: Central obesity (waist circumference in men> cm 94 in women> cm 80) hypertriglyceridemia (TG> mg / dl 150 or anti-lipid therapy), low levels of HDL-C: Men 130 or diastolic> 85 or under antihypertensive treatment), high blood sugar> mg / dl 100 or by treatment with a previous diagnosis DM2. | — |
Secondary
| Measure | Time frame |
|---|---|
| FBS. Timepoint: Before the intervention and three months after intervention. Method of measurement: In milligrams per deciliter of blood samples will be measured by standard devices; BT-3500 made in Italy and OLYMPUS AU400 models made in Japan.;Triglyceride. Timepoint: Before the intervention and three months after intervention. Method of measurement: In milligrams per deciliter of blood samples will be measured by standard devices; BT-3500 made in Italy and OLYMPUS AU400 models made in Japan.;High density lipoprotein- Cholesterol. Timepoint: Before the intervention and three months after intervention. Method of measurement: In milligrams per deciliter of blood samples will be measured by standard devices; BT-3500 made in Italy and OLYMPUS AU400 models made in Japan.;Waist circumference. Timepoint: Before the intervention and three months after intervention. Method of measurement: In cm by means of meters and when standing at the level of the umbilicus (between vertebrae L4 and L5) is measured.;Blood pressure. Timepoint: Before the intervention and three months after intervention. Method of measurement: Will be in millimeters of mercury. Mercury barometer by Richter and by calculating the average of 3 times measured in a sitting position and after ten minutes of rest will be measured. Diastolic blood pressure was measured using the fifth korotokof sound. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Hossein Doustkami
Ardabil University of Medical Sciences
Outcome results
None listed